patritumab deruxtecan

Action and Spectrum

Actions and Spectrum:  

Actions:  

Patritumab, an antibody-drug conjugate, targets HER3 using the topoisomerase I inhibitor DX 8951 to inhibit HER3-dependent signaling pathways and hinder cell proliferation and differentiation. 

Spectrum:  

A new drug, patritumab deruxtecan targets HER3 protein in EGFR-mutated NSCLC. FDA granted Priority Review for its application in Dec 2023. If approved, it’s for advanced NSCLC after two or more therapies.  

Drug Interaction

Adverse Reaction

Frequency defined  

Neutropenia (19%)  

Thrombocytopenia (20.9%)  

Anemia (14%)  

Constipation (34%)  

Decreased appetite (39%)  

Nausea (63%)  

Hypokalemia (5%)  

Leukopenia (10%)  

Asthenia (5%)  

Fatigue (6%) 

Black Box Warning

Black box warning  

None  

Contraindication / Caution

Contraindication/Caution:  

Contraindications  

Hypersensitivity  

Cautions  

Renal impairment  

Hepatic impairment  

Drug interactions  

CNS metastases  

Brain metastasis  

Pregnancy   

Breastfeeding  

Pregnancy / Lactation

Pregnancy consideration:   

No data is available regarding the administration of the drug during pregnancy.  

Breastfeeding warnings:   

No data is available regarding the excretion of drug in breast milk.  

Pregnancy category:  

Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.  

<b>Category B: There was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.  

Category C: There was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.     

Category D: Adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.     

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.     

Category N: No data is available for the drug under this category.  

Pharmacology

Pharmacology:  

Patritumab is a drug that targets the HER3 receptor and inhibits its activation, potentially blocking HER3-dependent cell signaling and growth. 

Pharmacodynamics:  

Patritumab effectively adjusted doses to handle gastrointestinal and cytopenia issues, with thrombocytopenia and neutropenia being the main severe adverse events. The discontinuation rate of treatment was low (9%), mainly due to these events, but none were singularly responsible.  

Pharmacokinetics:  

Limited data is available 

Adminstartion

Administration:  

Limited data available 

Patient Information Leaflet

Patient information leaflet  

Generic Name: patritumab deruxtecan  

Pronounced: pah-TRIH-too-mab der-UKS-te-can  

Why do we use patritumab deruxtecan?  

Patritumab deruxtecan targets the HER3 protein found in many cancers. It’s being tested in trials for effectiveness against HER3-expressing cancers like certain breast cancers. The drug delivers a powerful treatment directly to cancer cells via the HER3 receptor.